Strategic niche Target healthcare providers and laboratories requiring point-of-care haemostasis solutions, emphasizing the flagship microINR system as a compact, compliant option for INR monitoring in clinics and smaller labs.

Regulatory edge Highlight the company’s focus on stringent quality standards and patent-pending technology to position as a high-assurance supplier for hospital systems seeking reliable, compliant INR testing equipment.

Growth opportunities With revenue under one million and a modest funding round, pursue pilot programs, clinical collaborations, and early-adopter partnerships to demonstrate ROI and scale sales in microfluidics-based PoC devices.

Tech compatibility Leverage existing tech stack familiarity (cloud, web, and embedded components) to offer seamless integration, remote support, and service agreements that appeal to IT-enabled medical facilities.

Competitive positioning Differentiate from larger peers by market focus on microfluidics and Lab-on-a-Chip advantages for rapid INR testing, enabling compact devices suited for decentralised care and ambulatory settings.